Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
This important UK clinical trial is comparing a new medication called furmonertinib with standard chemotherapy. It's for people living with advanced non-small cell lung cancer that has a particular genetic alteration known as an EGFR exon 20 insertion mutation. Participants will be randomly assigned to receive either one of two doses of furmonertinib or chemotherapy. The main goal is to find out if furmonertinib is more effective and safer than current chemotherapy options for patients who haven't had previous treatment for their advanced lung cancer. This is a very common type of lung cancer, and finding new, better treatments is crucial. The study will help doctors understand the best way to treat this specific type of lung cancer.
Auf einen Blick
Worum geht es in dieser Studie?
This study, called FURVENT, is designed for people in the UK who have been diagnosed with locally advanced or metastatic non-small cell lung cancer. This means the cancer has either spread to nearby tissues or to other parts of the body. A key feature for this study is that participants must have a specific genetic change in their cancer, called an Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutation. This mutation can make the cancer respond differently to treatments.
The study aims to compare a new drug, furmonertinib, with platinum-based chemotherapy, which is a standard treatment. Furmonertinib is part of a group of drugs called targeted therapies that work by blocking specific signals that help cancer cells grow. Researchers want to see if furmonertinib, given as a daily tablet, is more effective and has fewer side effects than chemotherapy for this particular type of lung cancer.
About 375 patients will take part globally, and in the UK, patients will be split into three groups by chance (like drawing straws). One group will receive furmonertinib at a dose of 240 mg daily, another group will receive 160 mg daily, and the third group will receive standard platinum-based chemotherapy. This approach helps researchers get clear answers about which treatment works best. It's an 'open-label' study, meaning both you and your doctors will know which treatment you're receiving.
Wichtige Erkenntnisse
- New study for advanced non-small cell lung cancer with a specific genetic change (EGFR exon 20 insertion).
- Compares a new drug, furmonertinib, with standard chemotherapy.
- Aims to find improved first-line treatment options.
- Participation involves random assignment to different treatment groups.
- Close monitoring and support provided throughout the study.
Wer könnte berechtigt sein?
To be considered for this study, you must have a confirmed diagnosis of locally advanced or metastatic non-small cell lung cancer. It's crucial that your cancer has the specific EGFR exon 20 insertion mutation, which your doctors will have tested for in your tumour tissue or blood. Your cancer must also not be suitable for treatment with surgery or radiotherapy that would be intended to cure it.
This study is for people who have not yet received any previous treatment specifically for their advanced lung cancer. If you had chemotherapy, immunotherapy, or radiotherapy for lung cancer that hadn't spread (non-metastatic disease) in the past, you might still be eligible, but there needs to have been at least a 12-month break since your last treatment.
Even if you have had brain metastases (where the cancer has spread to the brain), you might still be able to join. This applies if they've been treated and are stable, or if they're new but not causing any symptoms. You must be at least 18 years old to participate.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Do you have locally advanced or metastatic non-small cell lung cancer?
- Has your cancer been tested and confirmed to have an EGFR exon 20 insertion mutation?
- Have you *not* had any previous treatment specifically for your advanced lung cancer?
- Sind Sie 18 Jahre alt oder älter?
- Is your cancer unsuitable for curative surgery or radiotherapy?
Was beinhaltet die Teilnahme?
If you decide to join this study, you will be randomly assigned to one of three treatment groups. This is like drawing lots, to ensure fairness. You could receive furmonertinib (an oral tablet) at one of two daily doses, or standard platinum-based chemotherapy given intravenously (into a vein). Your doctor and the study team will explain exactly what your specific treatment involves.
Taking part will involve regular hospital visits for assessments, which will include physical examinations, blood tests, and scans (like CT scans) to monitor your treatment and see how the cancer is responding. The frequency and duration of these visits will depend on which treatment group you are in and how you are responding. You will have ongoing follow-up with the study team to monitor your health and any side effects. The total duration of your participation will vary depending on your individual response to treatment and will be explained in detail by the study team.
Potenzielle Risiken und Vorteile
Locations (208)
- Arrivent Investigative SiteVerifizierte PostleitzahlDaphne, Vereinigte Staaten
- Arrivent Investigative SiteVerifizierte PostleitzahlYuma, Vereinigte Staaten
- Arrivent Investigative SiteVerifizierte PostleitzahlFayetteville, Vereinigte Staaten
- Arrivent Investigative SiteVerifizierte PostleitzahlBeverly Hills, Vereinigte Staaten
- Arrivent Investigative SiteVerifizierte PostleitzahlFullerton, Vereinigte Staaten
- Arrivent Investigative SiteVerifizierte PostleitzahlLong Beach, Vereinigte Staaten
- Arrivent Investigative SiteVerifizierte PostleitzahlLos Alamitos, Vereinigte Staaten
- Arrivent Investigative SiteVerifizierte PostleitzahlNapa, United States
- Arrivent Investigative SiteVerifizierte PostleitzahlOrange, Vereinigte Staaten
- Arrivent Investigative SiteVerifizierte PostleitzahlOrange, Vereinigte Staaten
- Arrivent Investigative siteVerifizierte PostleitzahlSacramento, Vereinigte Staaten
- Arrivent Investigative SiteVerifizierte PostleitzahlSan Diego, Vereinigte Staaten
Häufige Fragen
What is non-small cell lung cancer?
Non-small cell lung cancer is the most common type of lung cancer. It's different from small cell lung cancer under a microscope.
What is an EGFR exon 20 insertion mutation?
It's a specific change in the DNA of your cancer cells. Finding this change helps doctors choose treatments that target it directly.
What is furmonertinib?
Furmonertinib is a new oral medication designed to specifically block the signals that help lung cancer cells with the EGFR mutation to grow.
What is platinum-based chemotherapy?
This is a standard type of chemotherapy that uses drugs containing platinum to kill cancer cells, often used for lung cancer.
Werde ich wissen, welche Behandlung ich bekomme?
Yes, this is an 'open-label' study, which means both you and your doctor will know whether you are receiving furmonertinib or chemotherapy.
Wie Sie mehr erfahren können
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.